论文部分内容阅读
目的观察甘露聚糖肽治疗病毒感染性中性粒细胞减少症患儿的临床疗效。方法 50例患儿分别接受了对照组常规抗病毒药物治疗和试验组常规抗病毒药物治疗加甘露聚糖肽治疗,各25例。治疗有效的判断标准为末梢血中性粒细胞计数较治疗前至少增加30%以上。结果末梢血中性粒细胞计数显示治疗前试验组与对照组无统计学差异,分别为0.95±0.16与0.95±0.15;但治疗后试验组明显较对照组为高,分别为1.27±0.25与1.15±0.16,且试验组和对照组均较治疗前有明显改善。治疗有效率:试验组和对照组分别为96%(24/25)和28%(7/25),具有统计学差异。结论与病毒感染性中性粒细胞减少症患儿的常规抗病毒治疗相比,甘露聚糖肽进一步提升了中性粒细胞计数和改善了治疗有效率。
Objective To observe the clinical efficacy of mannan peptide in the treatment of children with viral infectious neutropenia. Methods Fifty children were treated with conventional antiviral drugs in the control group and conventional antiviral drugs plus mannan peptide in the experimental group, 25 cases each. Therapeutic effective criteria for peripheral blood neutrophil count at least 30% more than before treatment. Results The peripheral blood neutrophil count showed that there was no significant difference between the experimental group and the control group before treatment, which were 0.95 ± 0.16 and 0.95 ± 0.15, respectively. However, after treatment, the experimental group was significantly higher than the control group, 1.27 ± 0.25 and 1.15 ± 0.16, and the experimental group and the control group were significantly improved than before treatment. Therapeutic efficiency: 96% (24/25) and 28% (7/25), respectively, in the experimental and control groups, with statistical significance. Conclusions Mannopeptidyl peptide further enhances neutrophil count and improves treatment efficiency compared with conventional antiviral treatment in children with virally-infected neutropenia.